MeiraGTx Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MeiraGTx stock.
View analyst ratings for MeiraGTx or view top-rated stocks.

2 equities research analysts have issued twelve-month price objectives for MeiraGTx's stock. Their MGTX stock forecasts range from $18.00 to $46.00. On average, they predict MeiraGTx's stock price to reach $30.00 in the next year. This suggests a possible upside of 310.4% from the stock's current price.
View analysts' price targets for MeiraGTx or view top-rated stocks among Wall Street analysts.

MeiraGTx's stock was trading at $23.74 at the start of the year. Since then, MGTX stock has decreased by 69.2% and is now trading at $7.31.
View the best growth stocks for 2022 here.

MeiraGTx is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for MeiraGTx.

MeiraGTx Holdings plc (NASDAQ:MGTX) announced its quarterly earnings results on Thursday, May, 12th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.21. The firm had revenue of $5.63 million for the quarter, compared to the consensus estimate of $9.25 million. MeiraGTx had a negative trailing twelve-month return on equity of 47.01% and a negative net margin of 224.55%.
View MeiraGTx's earnings history.

Some companies that are related to MeiraGTx include Revolution Medicines (RVMD), SpringWorks Therapeutics (SWTX), Vaxcyte (PCVX), Adaptive Biotechnologies (ADPT), Sana Biotechnology (SANA), Vericel (VCEL), REGENXBIO (RGNX), Kymera Therapeutics (KYMR), Editas Medicine (EDIT), Alector (ALEC), Replimune Group (REPL), Arcellx (ACLX), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE) and iTeos Therapeutics (ITOS).
View all of MGTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), Kadmon (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).

(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

MeiraGTx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Royce & Associates LP (1.47%), State Street Corp (1.20%), Rhenman & Partners Asset Management AB (1.12%), Dimensional Fund Advisors LP (0.90%), Prosight Management LP (0.85%) and Assenagon Asset Management S.A. (0.67%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Elizabeth A Cook, Joel S Marcus, Life Sciences Maste Perceptive, Nicole Seligman, Richard Giroux, Robert J Wollin, Robert K Zeldin, Stuart Naylor and Thomas E Shenk.
View institutional ownership trends for MeiraGTx.

MGTX stock was sold by a variety of institutional investors in the last quarter, including Captrust Financial Advisors, Royce & Associates LP, Salem Investment Counselors Inc., UBS Group AG, TD Asset Management Inc., Jane Street Group LLC, Citigroup Inc., and Northern Trust Corp. Company insiders that have sold MeiraGTx company stock in the last two years include Alexandria Forbes, Elizabeth A Cook, Joel S Marcus, Richard Giroux, Stuart Naylor, and Thomas E Shenk.
View insider buying and selling activity for MeiraGTx or view top insider-selling stocks.

MGTX stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, Assenagon Asset Management S.A., Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Alyeska Investment Group L.P., Rhenman & Partners Asset Management AB, Russell Investments Group Ltd., and Bank of America Corp DE. Company insiders that have bought MeiraGTx stock in the last two years include Robert J Wollin, and Robert K Zeldin.
View insider buying and selling activity for MeiraGTx or or view top insider-buying stocks.

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MGTX stock can currently be purchased for approximately $7.31.

MeiraGTx (NASDAQ:MGTX) has a market capitalization of $326.83 million and generates $37.70 million in revenue each year. The company earns $-79.56 million in net income (profit) each year or ($1.970010) on an earnings per share basis.

MeiraGTx employs 287 workers across the globe.

MeiraGTx's mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The official website for MeiraGTx is www.meiragtx.com. The company can be reached via phone at (646) 860-7985 or via email at [email protected].